Dune Medical’s CEO Lori Chmura on the company’s $12.3M investment, plans to relocate, and making RF Spectroscopy the standard of care in cancer treatment to ensure that surgeons “get it all.”
“It’s [re-excision for breast conserving surgery] really a challenge that’s out there, and it’s a huge cost to the health-care system as well as a pretty big stress to the patient,” said Lori Chmura, CEO of Dune Medical Devices. “It’s really important to get all the cancer out the first time.”
Chmura recently spoke with Ellie Hensley of the Atlanta Business Chronicle to talk about the company’s recent $12.3M funding round, the future of RF spectroscopy in cancer care, and the numerous medtech resources available in the Southeast that has prompted the company to relocate to Atlanta.
“Our goal is to make MarginProbe a standard of care in breast conservation surgery,” Chmura said. “We’re in the process right now of developing technology to be able to detect microscopic residual cancer for other types of cancer as well.”
Hensley writes: “After breast cancer, Dune will focus on prostate cancer. The company’s goal is to expand MarginProbe’s capabilities to endoscopic, laparoscopic and robotic surgeries for cancers like pancreatic, lung, gastrointestinal and colon cancers.”
Originally founded in Israel, Dune is in the process of moving its U.S. headquarters from metro Philadelphia to Alpharetta.
“Atlanta has shown to be very open to working with Israeli startup companies, which is important to us,” Chmura said. “We are moving our headquarters to Alpharetta to really capitalize on the health IT market as well as the benefits of [the Southeastern Medical Device Association, located in Norcross, Ga.], the Global Center for Medical Innovation and some of the other great medical device organizations in Atlanta.”
You can read the full article here.
If you would like to learn more about RF spectroscopy’s capability to reduce positive margins for breast cancer patients or what the future of our technology holds for biopsy in breast cancer and other indications, contact firstname.lastname@example.org.